Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06269731
Other study ID # Thyroid cancer
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 2024
Est. completion date March 2026

Study information

Verified date February 2024
Source Assiut University
Contact salma mamdouh
Phone +201016297915
Email salmamamdouhmm@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. To identify the prevalence of both anxiety and depression in thyroid cancer patients 2. To assess quality of life in thyroid cancer patients


Description:

In recent years, increasing attention has been paid to mental health among cancer patients. Thyroid cancer is one of the most frequent endocrine neoplasia. It consists of 4 subtypes of papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer. Which is usually asymptomatic in the early stages, but symptoms such as neck pain, hoarseness, and dysphagia may occur as the disease progresses. TC is diagnosed by physical examination, analysis of thyroid hormone levels, imaging, and biopsy. Anxiety and depression are the most common psychological problems in the treatment of cancer patients and are related to the majority of medical diseases and physical symptoms. Studies have suggested that anxiety and depression are common in patients with thyroid cancer. Therefore, quality of life which includes psychological, social, and spiritual well-being, has become an important consideration . These findings highlight the importance of identifying thyroid cancer patients needs to allow better and more adequate care and support.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 159
Est. completion date March 2026
Est. primary completion date December 2025
Accepts healthy volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Age at or more than 18 years old 2. None of the patients had history of other psychiatric illness 3. Both sex 4. Accept to participate in the study Exclusion Criteria: 1. Age less than 18 years old 2. Previous history of other psychiatric illness 3. substance abuser or dependence 4. Refuse to participate in the study

Study Design


Intervention

Behavioral:
Hamilton depression Rating Scale
also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (3)

Alexander K, Lee SC, Georgiades S, Constantinou C. The "not so good" thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life. J Med Life. 2023 Mar;16(3):348-371. doi: 10.25122/jml-2022-0204. — View Citation

Dionisi-Vici M, Fantoni M, Botto R, Nervo A, Felicetti F, Rossetto R, Gallo M, Arvat E, Torta R, Leombruni P. Distress, anxiety, depression and unmet needs in thyroid cancer survivors: a longitudinal study. Endocrine. 2021 Dec;74(3):603-610. doi: 10.1007/s12020-021-02786-y. Epub 2021 Jun 18. — View Citation

Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, Gorges R. Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res. 2006 May;15(4):695-703. doi: 10.1007/s11136-005-3689-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary the prevalence of anxiety in thyroid cancer patients To identify the prevalence of anxiety in thyroid cancer patients by using Hamilton Anxiety Rating Scale baseline
Primary the prevalence of depression in thyroid cancer patients To identify the prevalence of depression in thyroid cancer patients by using Hamilton Depression Rating Scale baseline
Secondary assess quality of life in thyroid cancer patients Detect quality of life in patients with thyroid cancer by using Short form 36 Quality of life questionnaire baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Withdrawn NCT04224792 - Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors N/A
Completed NCT01728623 - A Study of E7080 in Subjects With Advanced Thyroid Cancer Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Recruiting NCT05025046 - NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
Not yet recruiting NCT03978351 - The Role of Midkine in Diagnosis of Thyroid Cancer
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02375451 - Effect of Childhood Radioiodine Therapy on Salivary Function N/A
Withdrawn NCT01994200 - Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients Phase 1/Phase 2
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00970359 - Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 N/A
Completed NCT00439478 - Dental Safety Profile of High-Dose Radioiodine Therapy Phase 4
Completed NCT00223158 - Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer N/A
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Completed NCT04876287 - Salivary dysfuncTion After Radioiodine Treatment
Recruiting NCT06073223 - Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer N/A
Recruiting NCT06037174 - Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
Recruiting NCT04952493 - Anlotinib or Penpulimab in Combination With RAI for DTC Phase 2